Trial Profile
A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms IMMpact2; KEEPsAKE 2
- Sponsors AbbVie; AbbVie Germany
- 03 Jun 2023 Results of post-hoc analysis of two studies KEEPsAKE 1 and 2 assessing improvements in patient-reported outcomes, presented at the 24th Annual Congress of the European League Against Rheumatism.
- 03 Jun 2023 Results of pooled analysis from KEEPsAKE 1 and 2, assessing the durability of the RZB treatment response on health-related quality of life (HRQoL) and patient-reported outcomes (PROs) in patients with PsA at Week 100, presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results (n=707 from studies KEEPsAKE 1 and KEEPsAKE 2 ) assessing response rates in PsA patients with limited (5 to 8) and extensive (more than 9) swollen joint after treatment with RZB to examine whether its efficacy differed according to the extent of joint involvement presented at the 24th Annual Congress of the European League Against Rheumatism